ArticleWorld journal of nephrology2025
Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients.
Article in World journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParathyroid hormone (PTH) levels may fluctuate in patients undergoing hemodialysis because of changes in calcium, phosphorus, and vitamin D levels. For these patients, the "Kidney Disease: Improving Global Outcomes" clinical practice guidelines recommend PTH levels be maintained in the range of two to nine times of the upper normal limit. Maintaining this balance is critical to prevent renal osteodystrophy. When the severity of hyperparathyroidism exceeds the recommended limits, vitamin D receptor agonists may be used for lowering PTH levels. Paricalcitol, as a biologically active vitamin D analog, is a selective activator of vitamin D responsive pathways. Both calcitriol and paricalcitol can be used as PTH-lowering agents. There is conflicting data about their comparative effectiveness for controlling hyperparathyroidism in patients undergoing hemodialysis and a meta-analysis revealed no differences between the two.
aimTo give real world data comparing paricalcitol and calcitriol as PTH-lowering agents in patients undergoing hemodialysis.
methodsPatients undergoing hemodialysis whose PTH levels exceeded nine times of the upper normal limit were enrolled in the study. Depending on patient preferences, they were either given calcitriol or paricalcitol. Intravenous calcitriol was given 2 μg at the end of each dialysis sessions, and intravenous paricalcitol was administered as 5 μg twice per week. Demographic data, calcium-phosphorus levels, change in PTH levels in 6 months, and ratios of 25% and 50% reductions in PTH levels were compared between the two groups.
resultsA total of 21 patients were enrolled in this comparative study, eight patients received paricalcitol and 13 were prescribed calcitriol. A 50% reduction in PTH levels could be achieved in five patients in the paricalcitol group (62.5%); only one patient in the calcitriol group achieved the same reduction (7.6%). The difference was statistically significant (
conclusionAlthough the PTH lowering effect of paricalcitol is stronger than calcitriol, both may help maintain PTH levels in the targeted range. Paricalcitol may be preferred for patients who have very high levels of PTH because it seems to cause a faster decline. Calcitriol may be preferred for a slower and limited decline. Prospective further studies with larger samples may be needed for a better comparison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.